Warning letter
Central Admixture Pharmacy Services, Inc.: warning letter of Mar 25, 2024
FDA warning letter 675065 · Division of Pharmaceutical Quality Operations IV
Key facts
| Reference number | 675065 |
|---|---|
| Company | Central Admixture Pharmacy Services, Inc. |
| Subject | CGMP/Drug Products/Adulterated |
| Issue date | Mar 25, 2024 |
| Posted date | May 21, 2024 |
| Issuing office | Division of Pharmaceutical Quality Operations IV |
| Product type | Drugs |
| CFR sections cited | 210.1(b), 211.165(a), 211.166(a), 211.165(e), 211.22, 211.192, 200.10(b), 211.42(c)(10)(vi), 211.68(b) |
| Inspection city | Phoenix |
| Inspection ZIP | 85043 |
| Inspection start date | Jun 21, 2023 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: